University of Southampton Institutional Repository

Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody

Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody
Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody
Described is the sequential administration of first a Treg depleting antibody mole- cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti- body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De- scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
WO2019020774-A2
Frendeus, Bjorn
3c6a6739-3319-4ae5-8019-d54470e2f444
Martensson, Linda
b2bfc6e1-efa5-4f34-9d56-f78b90accd17
Semmrich, Monika
913807d9-6ff8-424e-b616-ede82babb94c
Teige, Ingrid
203d3295-4d50-4067-aea7-c7f4e0be8d1a
Beers, Stephen
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Gray, Juliet
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Glennie, Martin
9f6f0eff-4560-48c2-80cd-0ec116110ded

Frendeus, Bjorn, Martensson, Linda, Semmrich, Monika, Teige, Ingrid, Beers, Stephen, Al-Shamkhani, Aymen, Gray, Juliet and Glennie, Martin (Inventors) (2019) Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody. WO2019020774-A2.

Record type: Patent

Abstract

Described is the sequential administration of first a Treg depleting antibody mole- cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti- body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De- scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.

Full text not available from this repository.

More information

Published date: 31 January 2019

Identifiers

Local EPrints ID: 445129
URI: http://eprints.soton.ac.uk/id/eprint/445129
PURE UUID: 6cfc2fc4-0c20-455a-abef-4cc05701c3f7
ORCID for Aymen Al-Shamkhani:

Catalogue record

Date deposited: 20 Nov 2020 17:32
Last modified: 20 Nov 2020 17:32

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using , developed at the University of Southampton, but available to everyone to use.

If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×